STARLIGHT THERAPEUTICS
Live / Allowed — Second extension granted (statement of use) (as of 03 Jun 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 11 Feb 2023 filing date already counts against anyone who files later.
Record
- Serial number
- 97790983
- Mark type
- Word mark
- Filed
- 11 Feb 2023
- Published for opposition
- 08 Apr 2025
- Attorney of record
- NIGAMNARAYAN ACHARYA
Goods and services
- Class 042 — Scientific and technological services: Pharmaceutical research and development services in the field of oncology, namely, neuro and central nervous system oncology; pharmaceutical drug discovery services in the field of oncology; scientific and medical research and development for pharmaceuticals, pharmaceutical preparations and substances in the field of oncology, namely, neuro and central nervous system oncology
Owner
- STARLIGHT THERAPEUTICS INC., Dallas, TX, US
- STARLIGHT THERAPEUTICS INC., Dallas, TX, US
Board proceedings on this mark
- Ex Parte Appeal No. 97790983 — Starlight Therapeuticals Inc., filed 17 Dec 2024 (Terminated)
Prosecution history
- 04 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Jun 2026 — SOU EXTENSION 2 GRANTED
- 03 Jun 2026 — SOU EXTENSION 2 FILED
- 03 Jun 2026 — SOU TEAS EXTENSION RECEIVED
- 04 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Dec 2025 — SOU EXTENSION 1 GRANTED
- 03 Dec 2025 — SOU EXTENSION 1 FILED
- 03 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Apr 2025 — PUBLISHED FOR OPPOSITION
- 02 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 Mar 2025 — EXPARTE APPEAL TERMINATED
- 13 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Feb 2025 — EX PARTE APPEAL-INSTITUTED